The Ca2+ release activated Ca2+ (CRAC) channel is an exciting new pharmacological target for the treatment of Inflammatory Bowel Disease (IBD) because it is upstream in the inflammatory cascade and absolutely necessary for immune responses. Calcium-selective CRAC channels become activated when T cells recognize antigen and allow calcium influx to the cytoplasm leading to increased NF-κB and NFAT-mediated gene expression driving inflammation. We have developed VV2003 which is a small molecule that blocks the CRAC channel and can be delivered orally.